Join the club for FREE to access the whole archive and other member benefits.

Ren Feng

Insilico Medicine's chief scientific officer (CSO) and Head of R&D

Dr. Feng Ren received his Ph.D. degree in chemistry from Harvard University in 2007. He then spent 11 years in the discovery and development of small molecule innovative drugs at GlaxoSmithKline (GSK), where he served as the principal scientist, program leader, director and head of chemistry of Neurodegeneration DPU, a global drug R&D unit in neurosciences in GSK.

In his career Dr. Ren successfully developed multiple preclinical candidate compounds/clinical phase I compounds for the treatment of non-small cell lung cancer, multiple sclerosis, psoriasis, inflammatory bowel disease, Parkinson's disease, and neuropathic pain.

In 2021, Dr. Ren joined Insilico Medicine as CSO, responsible for internal pipelines and external collaborations in drug discovery and development. 

Visit website:


See also: Company Insilico Medicine - Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Details last updated 07-Jun-2022

Ren Feng News

Insilico Medicine series D funding to grow its pipeline and create an AI-driven robotic drug discovery laboratory

Longevity Technology - 06-Jun-2022

Big data combined with laboratory automation - the pace of drug discovery is about to take off!

Topics mentioned on this page:
AI in Healthcare